What is Artera AI?
- Founders: Andre Esteva and Felix Y. Feng
- Launch: 2021, publicly launched in 2023
- Use Cases: Predicting therapeutic benefit in localized prostate cancer, Prognosis of long-term risks, such as metastasis or cancer mortality, Supporting personalized treatment planning and patient-clinician decision-making
- Technology: Multimodal artificial intelligence that merges digital histopathology image analysis with patient clinical data, proven effective in large phase III randomized trials.
ArteraAI is a precision health platform that personalizes cancer treatment, showcased first with prostate cancer. Its main product, the ArteraAI Prostate Test, uses advanced AI to analyze digital biopsy slides and related patient health information. Unlike traditional tests that only indicate how a disease might progress, ArteraAI can forecast both how the disease will advance and whether a patient will benefit from a specific treatment, helping doctors decide who should receive more aggressive treatment and who can safely avoid unnecessary procedures.
AI researcher Andre Esteva and clinician scientist Felix Y. Feng founded the company in 2021. In 2023, the company gained public recognition for its predictive and prognostic accuracy after developing the first clinically validated test. These predictive results are available within several days from existing tissue—no new biopsies are needed. By using strong evidence combined with advanced AI algorithms to better identify therapies and treatments, patients will have fewer unnecessary treatments, enjoy a better quality of life, and have improved, respectful discussions with their healthcare providers. The company mission is to deliver precision oncology both more widely and more reliably to build a better future.
Verified
